glp-1 drugs examples Market Overview: Agonists and the Obesity Market | Blog Understanding GLP-1 Agonists: Key Insights

Second, improvements in IR and glycaemic indices are most apparent in higher-burden phenotypes, particularly in women with impaired glucose tolerance/prediabetes or related metabolic comorbidities, where changes in HOMA-IR, fasting glucose and OGTT profiles are more pronounced and may plausibly reduce periconception metabolic risk

doi: 10.1177/15598276251344827

1.5% vs 0.9%point), dulaglutide (semaglutide 0.5 mg vs dulaglutide 0.75 mg, 1.5% vs 1.1%point

Lancet Diabetes Endocrinol 3(5):367381 van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH (2017) SGLT2 inhibition in the diabetic kidneyfrom mechanisms to clinical outcome

If youd like to notify the FDA about a side effect youve had with Januvia, visit MedWatch

CVOT, cardiovascular outcome trial